go-v.orgdoi

Fingolimod for the treatment of multiple sclerosis: a review of the evidence from the FREEDOMS and TRANSFORMS studies

Bhupendra Odhavji Khatri, John F Kramer · Clinical Investigation · 2011

  • DOI 10.4155/cli.11.19
  • Publisher OMICS Publishing Group
  • Type article
  • Issued 2011

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Clinical Investigation · OMICS Publishing Group · article · 2011

Abstract

Fingolimod (Gilenya®) is the first oral immunomodulating drug approved for relapsing–remitting multiple sclerosis. Its novel mechanism of action inhibits the egress of autoreactive B and T cells from lymph nodes, thus preventing them from crossing into the CNS. Two recent large Phase III clinical trials both met their primary end points clearing the way for approval by the US FDA in September 2010. Despite robust clinical efficacy, safety concerns arose in both trials, including, but not limited to, increased risk of infection, cardiac issues and a higher incidence of cancer.

Further long-term data will clarify these safety issues to enable clinicians to feel comfortable when prescribing fingolimod on a routine basis. This article will review the clinical trial data from the Trial Assessing Injectable Interferon versus FTY720 Oral in Relapsing–Remitting Multiple Sclerosis (TRANSFORMS) and FTY720 Research Evaluating Effects of Daily Oral therapy in Multiple Sclerosis (FREEDOMS) studies.

Open the resolved locator · 10.4155/cli.11.19

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-20 10:01 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://doi.org/10.4155/cli.11.19
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.